Oncotelic Therapeutics Inc OTLC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OTLC is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.04
- Day Range
- $0.04–0.04
- 52-Week Range
- $0.01–0.05
- Bid/Ask
- $0.04 / $0.04
- Market Cap
- $15.19 Mil
- Volume/Avg
- 2,501 / 91,543
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 203.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.87%
Company Profile
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
- Website
- https://www.oncotelic.com
Valuation
|
Metric
|
OTLC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.18 |
Price/Sales | 203.39 |
Price/Cash Flow | — |
Price/Earnings
OTLC
Financial Strength
|
Metric
|
OTLC
|
|---|---|
Quick Ratio | 0.02 |
Current Ratio | 0.02 |
Interest Coverage | −6.05 |
Quick Ratio
OTLC
Profitability
|
Metric
|
OTLC
|
|---|---|
Return on Assets (Normalized) | −4.73% |
Return on Equity (Normalized) | −10.22% |
Return on Invested Capital (Normalized) | −1.84% |
Return on Assets
OTLC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kmtytnssxr | Jptxh | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zybwnrdw | Pywxrph | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rfrwdzwc | Zqybvz | $99.5 Bil | |
MRNA
| Moderna Inc | Lscmjrbn | Nwl | $38.8 Bil | |
ARGX
| argenx SE ADR | Jfmqyjyc | Smf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rypldnq | Fhmp | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tyfnqyzgv | Lrmclbr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bpnxblc | Rncgtv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wtvfktgx | Qdtjhn | $12.5 Bil | |
INCY
| Incyte Corp | Xcjtypf | Drcvdz | $11.6 Bil |